Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP

Blood

Volumn 111, Issue 12, 2008, Pages 5509-5514

  Malumbres, Raquel ^a   Chen, Jun ^a   Tibshirani, Rob ^b   Johnson, Nathalie A ^c   Sehn, Laurie H ^d   Natkunam, Yaso ^e   Briones, Javier ^f   Advani, Ranjana ^e   Connors, Joseph M ^d   Byrne, Gerald E ^g   Levy, Ronald ^e   Gascoyne, Randy D ^c   Lossos, Izidore S ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Department of Pathology ^*  (Spain)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FORMALDEHYDE; PARAFFIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

6 GENE MODEL; ADOLESCENT; ADULT; AGED; ARTICLE; BCL6 GENE; CALCULATION; CANCER MORTALITY; CANCER SURVIVAL; CCND2 GENE; EVALUATION; FN1 GENE; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LMO2 GENE; MODEL; OVERALL SURVIVAL; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA EXTRACTION; SCYA3 GENE; TREATMENT OUTCOME; BIOLOGICAL MODEL; BIOPSY; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MODELS, GENETIC; MULTIVARIATE ANALYSIS; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 47049128763     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-136374     Document Type: Article

References (29)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
2. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:995-1007.
3. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26:447-454.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohisto-chemistry using a tissue microarray. Blood. 2004;103:275-282.
5. Sáez AI, Sáez AJ, Artiga MJ, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol. 2004;164:613-622.
6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
8. Rosenwald A, Wright G, Chan WC. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
9. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25:805-812.
10. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner
11. A. Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003:100:9991-9996.
12. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1837.
13. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-1861.
14. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
15. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
16. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
17. Sehn LH. Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027-5033.
18. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NGI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
20. Jaffa ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of the hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
21. Chen J, Byrne GE Jr. Lossos IS. Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues. Diagn Mol Pathol. 2007:16:61-72.
22. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 2003;17:789-795.
23. Cox D. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972;34:187-220.
24. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DL-BCL). Blood. 2003;101:4279-4284.
25. Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica. 2006;91:715-716.
26. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DL-BCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207-4213.
27. Masuda N, Ohnishi T. Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999;27:4436-4443.
28. Proost P, Wuyts A, van Damme J. The role of chemokines in inflammation. Int J Clin Lab Res. 1996;26:211-223.
29. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A. 2003;100:1926-1930.